$7.565
Revenue is down for the last 3 quarters, 74.37M → 66.88M (in $), with an average decrease of 5.2% per quarter
Netprofit is down for the last 3 quarters, -2.11M → -10.86M (in $), with an average decrease of 127.0% per quarter
0.92%
Downside
Day's Volatility :3.85%
Upside
2.95%
67.9%
Downside
52 Weeks Volatility :71.74%
Upside
11.98%
Period | Mimedx Group, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 20.72% | -1.1% | 0.0% |
6 Months | 132.73% | 1.6% | 0.9% |
1 Year | 153.27% | 4.2% | 3.1% |
3 Years | 7.19% | 24.2% | 17.1% |
Market Capitalization | 916.1M |
Book Value | - $0.11 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.17 |
PEG Ratio | 2.97 |
Wall Street Target Price | 12.06 |
Profit Margin | -4.28% |
Operating Margin TTM | -0.43% |
Return On Assets TTM | -0.46% |
Return On Equity TTM | -15.91% |
Revenue TTM | 295.0M |
Revenue Per Share TTM | 2.58 |
Quarterly Revenue Growth YOY | 21.5% |
Gross Profit TTM | 219.5M |
EBITDA | 2.5M |
Diluted Eps TTM | -0.17 |
Quarterly Earnings Growth YOY | 4.0 |
EPS Estimate Current Year | 0.07 |
EPS Estimate Next Year | 0.3 |
EPS Estimate Current Quarter | -0.02 |
EPS Estimate Next Quarter | 0.03 |
What analysts predicted
Upside of 59.42%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 321.1M | ↑ 31.07% |
Net Income | 64.7M | ↑ 440.56% |
Net Profit Margin | 20.16% | ↑ 15.27% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 359.1M | ↑ 11.82% |
Net Income | -30.0M | ↓ 146.32% |
Net Profit Margin | -8.35% | ↓ 28.51% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 359.1M | ↑ 0.0% |
Net Income | -30.0M | ↑ 0.0% |
Net Profit Margin | -8.35% | ↑ 0.0% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 299.3M | ↓ 16.67% |
Net Income | -25.6M | ↓ 14.67% |
Net Profit Margin | -8.55% | ↓ 0.2% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 258.6M | ↓ 13.58% |
Net Income | -10.3M | ↓ 59.79% |
Net Profit Margin | -3.98% | ↑ 4.57% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 267.8M | ↑ 3.57% |
Net Income | -36.8M | ↑ 257.58% |
Net Profit Margin | -13.73% | ↓ 9.75% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 58.9M | ↓ 12.63% |
Net Income | -10.5M | ↓ 573.54% |
Net Profit Margin | -17.81% | ↓ 21.1% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 66.9M | ↑ 13.57% |
Net Income | -10.9M | ↑ 3.61% |
Net Profit Margin | -16.25% | ↑ 1.56% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 67.7M | ↑ 1.21% |
Net Income | -8.4M | ↓ 22.47% |
Net Profit Margin | -12.45% | ↑ 3.8% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 74.4M | ↑ 9.88% |
Net Income | -2.1M | ↓ 74.96% |
Net Profit Margin | -2.84% | ↑ 9.61% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 71.7M | ↓ 3.63% |
Net Income | -4.9M | ↑ 131.33% |
Net Profit Margin | -6.81% | ↓ 3.97% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 66.9M | ↓ 6.69% |
Net Income | -10.9M | ↑ 122.66% |
Net Profit Margin | -16.25% | ↓ 9.44% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 121.3M | ↓ 37.26% |
Total Liabilities | 47.5M | ↓ 21.25% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 122.8M | ↑ 1.31% |
Total Liabilities | 73.2M | ↑ 54.22% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 122.8M | ↑ 0.0% |
Total Liabilities | 73.2M | ↑ 0.0% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 167.2M | ↑ 36.08% |
Total Liabilities | 132.8M | ↑ 81.4% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 187.9M | ↑ 12.42% |
Total Liabilities | 95.4M | ↓ 28.18% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 171.4M | ↓ 8.78% |
Total Liabilities | 96.9M | ↑ 1.65% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 174.4M | ↓ 7.18% |
Total Liabilities | 89.4M | ↓ 6.26% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 168.7M | ↓ 3.31% |
Total Liabilities | 89.8M | ↑ 0.44% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 172.8M | ↑ 2.45% |
Total Liabilities | 99.8M | ↑ 11.19% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 171.4M | ↓ 0.79% |
Total Liabilities | 96.9M | ↓ 2.91% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 168.2M | ↓ 1.91% |
Total Liabilities | 93.6M | ↓ 3.42% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 176.4M | ↑ 4.89% |
Total Liabilities | 96.6M | ↑ 3.14% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 62.9M | ↑ 143.69% |
Investing Cash Flow | -5.4M | ↓ 53.78% |
Financing Cash Flow | -60.4M | ↑ 638.14% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 35.8M | ↓ 43.13% |
Investing Cash Flow | -9.2M | ↑ 70.84% |
Financing Cash Flow | -8.9M | ↓ 85.21% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 35.8M | ↑ 0.0% |
Investing Cash Flow | 504.0K | ↓ 105.47% |
Financing Cash Flow | -8.9M | ↑ 0.0% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -39.4M | ↓ 210.1% |
Investing Cash Flow | -4.6M | ↓ 1003.77% |
Financing Cash Flow | 62.9M | ↓ 803.59% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -2.0M | ↓ 94.97% |
Investing Cash Flow | -3.4M | ↓ 25.47% |
Financing Cash Flow | -3.4M | ↓ 105.33% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -10.2M | ↑ 216.31% |
Investing Cash Flow | -148.0K | ↓ 52.87% |
Financing Cash Flow | -1.0M | ↓ 4809.09% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.0M | ↓ 70.61% |
Investing Cash Flow | -429.0K | ↑ 189.86% |
Financing Cash Flow | 260.0K | ↓ 125.1% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 959.0K | ↓ 131.91% |
Investing Cash Flow | -374.0K | ↓ 12.82% |
Financing Cash Flow | 130.0K | ↓ 50.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -4.0M | ↓ 28.02% |
Investing Cash Flow | -677.0K | - |
Financing Cash Flow | -4.0K | ↓ 106.06% |
Sell
Neutral
Buy
Mimedx Group, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Mimedx Group, Inc. | 5.73% | 132.73% | 153.27% | 7.19% | 25.4% |
![]() Moderna, Inc. | -12.64% | -32.32% | -18.59% | 40.95% | 434.62% |
![]() Regeneron Pharmaceuticals, Inc. | 0.2% | 0.68% | 18.02% | 45.57% | 106.06% |
![]() Novo Nordisk A/s | -2.18% | 18.08% | 84.58% | 165.14% | 289.05% |
![]() Seagen, Inc. | 3.05% | 4.69% | 54.33% | 11.57% | 175.61% |
![]() Vertex Pharmaceuticals Incorporated | -0.55% | 11.62% | 19.58% | 30.6% | 81.41% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Mimedx Group, Inc. | NA | NA | 2.97 | 0.07 | -0.16 | 0.0 | 0.0 | -0.11 |
![]() Moderna, Inc. | 34.67 | 34.67 | 0.0 | -3.66 | 0.07 | 0.01 | 0.0 | 44.49 |
![]() Regeneron Pharmaceuticals, Inc. | 21.73 | 21.73 | 9.01 | 41.82 | 0.19 | 0.1 | 0.0 | 225.94 |
![]() Novo Nordisk A/s | 43.3 | 43.3 | 2.03 | 1.65 | 0.82 | 0.22 | 0.01 | 2.52 |
![]() Seagen, Inc. | NA | NA | 18.53 | -3.52 | -0.26 | -0.13 | 0.0 | 13.96 |
![]() Vertex Pharmaceuticals Incorporated | 26.94 | 26.94 | 0.41 | 14.71 | 0.25 | 0.16 | 0.0 | 60.01 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Mimedx Group, Inc. | Buy | $916.1M | 25.4% | NA | -4.28% |
![]() Moderna, Inc. | Buy | $37.3B | 434.62% | 34.67 | 11.33% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $90.4B | 106.06% | 21.73 | 33.93% |
![]() Novo Nordisk A/s | Buy | $410.6B | 289.05% | 43.3 | 33.4% |
![]() Seagen, Inc. | Hold | $40.6B | 175.61% | NA | -33.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $90.2B | 81.41% | 26.94 | 35.4% |
BlackRock Inc
Vanguard Group Inc
Paradigm Capital Management, Inc.
State Street Corporation
Geode Capital Management, LLC
Richmond Brothers Inc
Mimedx Group, Inc.’s price-to-earnings ratio stands at None
Read Moremimedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. the company processes the human placental tissue utilizing its proprietary purion® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. mimedx has supplied more than two million allografts, through both direct and consignment shipments. for additional information, please visit www.mimedx.com.
Organization | Mimedx Group, Inc. |
Employees | 867 |
CEO | Mr. K. Todd Newton |
Industry | Biotechnology |
Innovator S&p 500 Power-jan
$7.57
-2.39%
Energy Fuels Inc/canada
$7.57
-2.39%
Cohen & Steers Closed-end Op
$7.57
-2.39%
Despegar.com Corp
$7.57
-2.39%
Sonder Holdings Inc
$7.57
-2.39%
Flexshares Quality Dividend
$7.57
-2.39%
Star Group Lp
$7.57
-2.39%
Gamco Global Gold Natural Resources & Income Trust
$7.57
-2.39%
Radnet Inc
$7.57
-2.39%